EUVIMEDEUVIMED entdecken
Crossref

A high-throughput zebrafish screen identifies novel candidate treatments for kaposiform lymphangiomatosis (KLA)

Ivan Bassi iD, Amani Jabali iD, Lotan Levin iD, Giuseppina Lambiase iD, Noga Moshe iD, Naama Farag iD, Yaara Tevet iD, Gal Perlmoter iD, Shany Egozi iD, Gil S Leichner iD, Polina Geva iD, Aviv Barzilai iD und 7 weitere

Journal of Experimental Medicine · 2025

DOI: 10.1084/jem.20240513 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2025. Verfasst von Ivan Bassi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel. Hauptthemen laut MEDLINE: Zebrafish, High-Throughput Screening Assays, Kasabach-Merritt Syndrome, Hemangioendothelioma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: European Research Council, Orphan Disease Center, Estate of Emile Mimran.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kaposiform lymphangiomatosis (KLA) is a rare and aggressive disease caused by a somatic activating NRAS mutation (p.Q61R) in lymphatic endothelial cells (LECs). The development of new therapeutic avenues is hampered by the lack of animal models faithfully replicating the clinical manifestations of KLA. Here, we established a novel zebrafish model of KLA by conditionally expressing the human NRAS mutation in venous and lymphatic ECs. Mutant embryos recapitulate key clinical features of KLA, including dilated lymphatics and pericardial edema, which are reversed by trametinib, a MEK inhibitor used in KLA treatment. Leveraging this model in combination with an AI-based high-throughput drug screening platform, we identify cabozantinib, a tyrosine kinase inhibitor, and GSK690693, a competitive pan-Akt kinase inhibitor, as promising candidates for treating KLA. Notably, both drugs normalized sprouting and migration of cultured LECs from a KLA patient. Overall, our novel zebrafish model provides a powerful platform to dissect KLA pathogenesis and identify new therapeutic avenues.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ZebrafishHigh-Throughput Screening AssaysKasabach-Merritt SyndromeHemangioendotheliomaAnimalsHumansDisease Models, AnimalEndothelial CellsProtein Kinase InhibitorsPyridonesMutationPyrimidinonesCell MovementPyridinesAnimals, Genetically ModifiedSarcoma, Kaposi

Substanzen

Protein Kinase InhibitorsPyridonesPyrimidinonesPyridinestrametinib

Autor:innen und Institutionen

  • Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv, Israel.
  • Department of Dermatology, Sheba Medical Center, Ramat Gan, Israel.
  • Department of Pathology, Sheba Medical Center, Ramat Gan, Israel.
  • IDEA Bio-Medical Ltd. , Rehovot, Israel.
  • The Maurice and Vivienne Wohl Institute for Drug Discovery, The Nancy and Stephen Grand Israel National Center for Personalized Medicine (INCPM), Weizmann Institute of Science , Rehovot, Israel.

ORCID-Profile: Ivan Bassi, Amani Jabali, Lotan Levin, Giuseppina Lambiase, Noga Moshe, Naama Farag, Yaara Tevet, Gal Perlmoter, Shany Egozi, Gil S Leichner, Polina Geva, Aviv Barzilai, Camila Avivi, Jonathan Long, Jason J Otterstrom, Yael Paran, Haim Barr, Karina Yaniv, Shoshana Greenberger

Förderung

  • European Research Council
  • Orphan Disease Center
  • Estate of Emile Mimran
  • Maurice and Vivienne Wohl Biology Endowment
  • Brenden-Mann Women's Innovation Impact Fund
  • Lymphatic Malformation Institute
  • Sheba Medical Center
  • Weizmann Institute of Science

Zitieren

APA

Bassi, I., Jabali, A., Levin, L., Lambiase, G., Moshe, N., Farag, N., Tevet, Y., Perlmoter, G., Egozi, S., Leichner, G. S., Geva, P., Barzilai, A., Avivi, C., Long, J., Otterstrom, J. J., Paran, Y., Barr, H., Yaniv, K., & Greenberger, S. (2025). A high-throughput zebrafish screen identifies novel candidate treatments for kaposiform lymphangiomatosis (KLA). Journal of Experimental Medicine. https://doi.org/10.1084/jem.20240513

Vancouver

Bassi I, Jabali A, Levin L, Lambiase G, Moshe N, Farag N, et al. A high-throughput zebrafish screen identifies novel candidate treatments for kaposiform lymphangiomatosis (KLA). Journal of Experimental Medicine. 2025. doi:10.1084/jem.20240513

BibTeX
@article{Bassi2025,
  author = {Bassi, Ivan and Jabali, Amani and Levin, Lotan and Lambiase, Giuseppina and Moshe, Noga and Farag, Naama and Tevet, Yaara and Perlmoter, Gal and Egozi, Shany and Leichner, Gil S and Geva, Polina and Barzilai, Aviv and Avivi, Camila and Long, Jonathan and Otterstrom, Jason J and Paran, Yael and Barr, Haim and Yaniv, Karina and Greenberger, Shoshana},
  title = {A high-throughput zebrafish screen identifies novel candidate treatments for kaposiform lymphangiomatosis (KLA)},
  journal = {Journal of Experimental Medicine},
  year = {2025},
  doi = {10.1084/jem.20240513}
}
Kostenlos starten →